What is Lunaphore Technologies?
Headquartered in Switzerland, Lunaphore Technologies specializes in the development of next-generation tissue autostainers. The company is fundamentally changing the landscape of pathology by bringing omic-like approaches to in-situ tissue analytics. By automating complex staining processes, Lunaphore enables researchers and clinicians to obtain high-resolution, reproducible data from tissue samples, which is critical for advancing precision medicine and oncology diagnostics. Their market position is defined by a unique synthesis of deep-tech engineering and biological insight, allowing them to address the growing demand for high-throughput, automated diagnostic tools in both research and clinical environments.
How much funding has Lunaphore Technologies raised?
Lunaphore Technologies has raised a total of $92.9M across 7 funding rounds:
Series A
$2.1M
Private Equity
$6.1M
Series B
$5.3M
Series C
$23.6M
Other Financing Round
$2.1M
Debt
$10M
Series D
$43.7M
Series A (2015): $2.1M with participation from Redalpine Venture Partners
Private Equity (2017): $6.1M led by Redalpine Venture Partners, Occident, Zu00fchlke Ventures, and Polytech Ecosystem Ventures
Series B (2018): $5.3M supported by Occident and Zürcher Kantonalbank
Series C (2020): $23.6M featuring Redalpine Venture Partners, OCCIDENT, Alpana Ventures, and PHC Holdings Corporation
Other Financing Round (2020): $2.1M backed by Swiss Entrepreneurs Fund
Debt (2022): $10M with participation from Norgine Ventures Management
Series D (2023): $43.7M led by Ernst Göhner, PHC Group, and Redalpine
Key Investors in Lunaphore Technologies
Redalpine Venture Partners
A thesis-driven venture capital firm established in 2006 that specializes in supporting highly technical companies at the intersection of software and science.
Occident
An international, owner-managed venture capital investor focusing on deep-tech startups within the life sciences and high-tech sectors across Germany and Switzerland.
PHC Group
A global healthcare company specializing in diagnostic services and innovative medical technologies, providing comprehensive solutions to healthcare facilities worldwide.
What's next for Lunaphore Technologies?
With the recent influx of $43.7M, Lunaphore Technologies is well-positioned to expand its commercial footprint and further refine its diagnostic platform. The strategic focus will likely shift toward scaling manufacturing capabilities and accelerating the regulatory approval processes for its latest generation of autostainers. As the company continues to integrate its technology into global healthcare systems, the emphasis will remain on enhancing the precision of cancer diagnostics and fostering partnerships with major diagnostic service providers. This capital deployment will be instrumental in maintaining the company's competitive edge in the rapidly evolving field of digital pathology and spatial biology.
See full Lunaphore Technologies company page
